ReviewInflammopharmacology2026
Microglial synaptic pruning in early Alzheimer's disease: emerging roles of the IL-1β-NLRP3 axis.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease is a progressive neurodegenerative disorder characterized by early synaptic dysfunction that precedes overt neuronal loss and cognitive decline. While amyloid-β and tau pathologies have long dominated disease models, growing evidence highlights neuroinflammation as a critical driver of early pathological changes. In particular, microglia-mediated inflammatory signaling has emerged as a key regulator of synaptic integrity. This review focuses on the interleukin-1β (IL-1β)-NLRP3 inflammasome axis as a central mechanism linking innate immune activation to aberrant synaptic pruning in early Alzheimer's disease. Activation of the NLRP3 inflammasome in microglia by amyloid-β and related danger signals leads to caspase-1-dependent maturation and release of IL-1β. Elevated IL-1β amplifies inflammatory signaling, alters microglial phenotype, and promotes complement-mediated tagging of synapses, resulting in excessive elimination of functional synaptic connections. Experimental evidence from in vitro systems, transgenic mouse models, and pharmacological inhibition studies supports a causal role for this axis in synapse loss, impaired synaptic plasticity, and cognitive deficits. Importantly, these inflammatory and synaptic alterations occur at early disease stages, underscoring their relevance to disease initiation rather than late-stage neurodegeneration. The review further discusses the impact of IL-1β-NLRP3 signaling on neuronal network function, hippocampal plasticity, and cognitive performance, as well as its translational implications. Therapeutic strategies targeting inflammasome activation or IL-1β signaling show promise in preserving synaptic function in preclinical models. Overall, the IL-1β-NLRP3-synapse axis represents a compelling framework for understanding early Alzheimer's disease pathology and offers a rational target for early intervention strategies to slow disease progression.
Indexed as
Identifiers
42432341What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.